source
- Mirum's hepatitis D antibody brelovitug meets primary endpoint in phase 3 trialMirum Pharmaceuticals announced that its experimental antiviral monoclonal antibody brelovitug achieved the primary efficacy goal in a phase 3 study for hepatitis D. The trial results continue a s…
- Democratic committee chairs send letters to 27 drugmakers demanding details on Trump-era MFN pricing agreementsIncoming Democratic chairs of the Senate Finance Committee and the House Energy and Commerce, Ways and Means, and Education and Labor committees have issued a new round of letters to all 27 drugmak…